Correlation Between Takeda Pharmaceutical and Blueprint Medicines

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Takeda Pharmaceutical and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Takeda Pharmaceutical and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Takeda Pharmaceutical Co and Blueprint Medicines Corp, you can compare the effects of market volatilities on Takeda Pharmaceutical and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Takeda Pharmaceutical with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Takeda Pharmaceutical and Blueprint Medicines.

Diversification Opportunities for Takeda Pharmaceutical and Blueprint Medicines

-0.55
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Takeda and Blueprint is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Takeda Pharmaceutical Co and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Takeda Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Takeda Pharmaceutical Co are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Takeda Pharmaceutical i.e., Takeda Pharmaceutical and Blueprint Medicines go up and down completely randomly.

Pair Corralation between Takeda Pharmaceutical and Blueprint Medicines

Considering the 90-day investment horizon Takeda Pharmaceutical Co is expected to generate 0.32 times more return on investment than Blueprint Medicines. However, Takeda Pharmaceutical Co is 3.13 times less risky than Blueprint Medicines. It trades about 0.19 of its potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.03 per unit of risk. If you would invest  1,317  in Takeda Pharmaceutical Co on December 30, 2024 and sell it today you would earn a total of  188.00  from holding Takeda Pharmaceutical Co or generate 14.27% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Takeda Pharmaceutical Co  vs.  Blueprint Medicines Corp

 Performance 
       Timeline  
Takeda Pharmaceutical 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Takeda Pharmaceutical Co are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain basic indicators, Takeda Pharmaceutical disclosed solid returns over the last few months and may actually be approaching a breakup point.
Blueprint Medicines Corp 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound primary indicators, Blueprint Medicines is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Takeda Pharmaceutical and Blueprint Medicines Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Takeda Pharmaceutical and Blueprint Medicines

The main advantage of trading using opposite Takeda Pharmaceutical and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Takeda Pharmaceutical position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.
The idea behind Takeda Pharmaceutical Co and Blueprint Medicines Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Stocks Directory
Find actively traded stocks across global markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance